AFFIDAVIT OF JEFF KARR
`
`I, JeffKarr, state as follows:
`
`1.
`
`I am the Archivist at the American Society for Microbiology ("ASM"). I
`
`have held this position at the ASM for over 20 years. Specifically, I was the
`
`Archivist at the ASM in 1996. I make this declaration of my own personal
`
`knowledge.
`
`2.
`
`I manage the ASM collection at the Albin 0. Kuhn Library & Gallery at the
`
`University of Maryland, Baltimore County. My job includes receiving ASM
`
`documents from headquarters, such as documents and publications related to
`
`ASM scientific meetings, including the abstract books for these meetings. I
`
`catalog and archive these documents, and ensure that they are available to
`
`the public.
`
`3.
`
`I am knowledgeable regarding ASM' s publication procedures and have
`
`access to ASM' s publication records and archives which go back to ASM' s
`
`formation in 1899.
`
`4.
`
`I have been asked to report the date that the following abstracts, presented at
`
`the 36th Interscience Conference on Antimicrobial Agents and
`
`Chemotherapy ("ICAAC"), an annual meeting of the ASM, were made
`
`available to the public: Abstract F78 (H. Ogura, et al., "KP-1 03 a Novel
`
`ARGENTUM EX1044
`
`Page 1
`
`

`

`Affidavit of JeffKarr
`Page2
`
`Topical Antifungal Triazole: Structure-Activity Relationships of
`
`Azolylamine Derivatives"), Abstract F79 (Y. Tatsumi, et. al., "In Vitro
`
`Activity ofKP-103, a Novel Topical Antifungal Triazole"), and Abstract
`
`F80 (Y. Tatsumi, et al., "Therapeutic Efficacy ofKP-103, a Novel Topical
`
`Antifungal Triazole, on Experimental Superficial Mycoses") (collectively,
`
`"Kaken Abstracts").
`
`5.
`
`Based on my experience working at ASM, I confirm that it is the ASM' s
`
`usual practice to distribute scientific meeting abstracts either before the start
`
`6.
`
`7.
`
`of the scientific meeting or during the meeting itself.
`
`The 36th ICAAC was held from September 15- 18, 1996.
`
`ASM's records show that the Kaken Abstracts were published in a book
`
`("Abstracts Book") that was made available to conference participants (i.e.,
`
`the public) both before the start of and during the 36th ICAAC. Attached
`
`hereto as Exhibit A is a true and accurate copy of various pages from the
`
`Abstracts Book, including the title page, the copyright page, page iii
`
`(containing the table of contents), and page 113 (containing the Kaken
`
`Abstracts).
`
`8.
`
`ASM publishes a monthly newsletter called the ASM News. I recall that, in
`
`1996, the ASM News was printed and mailed to ASM members each month.
`
`Page 2
`
`

`

`Affidavit of JeffKarr
`Page3
`
`9.
`
`The August 1996, issue of the ASM News contained a supplement entitled
`
`"Preliminary Program of the 36th ICAAC" ("Preliminary Program.") A true
`
`and accurate copy of various pages of the Preliminary Program is attached
`
`hereto as Exhibit B.
`
`10.
`
`I am not aware of the exact date that the August 1996 issue of the ASM
`
`News and the Preliminary Program were mailed to ASM members. Based
`
`on my experience at ASM, however, it was likely mailed to members at the
`
`end of July or the beginning of August 1996.
`
`11.
`
`Page 4 of the Preliminary Program indicates that the Abstracts Book was
`
`provided to attendees of the 36th ICAAC during the preregistration period.
`
`The preregistration period occurred prior to the start of the meeting (i.e.
`
`before September 15, 1996). Specifically, page 4 of the Preliminary
`
`Program states that:
`
`All registrants will receive a copy of the Program and the Abstracts
`Book as part of the registration fee. These books are mailed to all
`U.S. and Canadian preregistrants. Canadian preregistrants can pay an
`optional fee of $20 to have these books shipped via Federal Express
`(see registration fmm).
`Preregistered attendees in international
`locations may receive the Program and Abstracts Books (via Federal
`Express) before the meeting for an additional fee of $30 (see
`registration form).
`If the optional delivery fee is not paid by an
`international preregistrant, then one copy of each book can be picked
`up on site at the Preregistration Desk by presenting the Attendee
`Locator card that is mailed with the badge. Every effort is made to
`
`Page 3
`
`

`

`Affidavit of JeffKarr
`Page4
`
`ensure that Abstracts Books are available at the meeting for purchase
`by on-site registrants. However, should on-site registration exceed
`expectations, we cannot guarantee that our supply of Abstracts Books
`will meet the needs of all on-site registrants. If available, copies of the
`Abstracts Book may be ordered after the meeting by calling ASM
`Publication Sales at 703-787-3305.
`
`12. The statements on page 4 of the Preliminary Program confirm that the
`
`Abstract Book for the 36th ICAAC, which contains the Kaken Abstracts, was
`
`available to preregistered meeting participants in advance of the start of the
`
`conference (i.e. before September 15, 1996). Page 4 indicates that the
`
`Abstracts Book was mailed to U.S. and Canadian preregistrants, and that
`
`preregistered attendees in international locations could receive the Program
`
`and Abstracts Books (via Federal Express) before the meeting by paying an
`
`additional fee of $30.
`
`13. The Preliminary Program does not indicate the earliest exact date that the
`
`Abstracts Book was made available to the public. However, the cover page
`
`of the Preliminary Program indicates that the discounted preregistration
`
`deadline was July 12, 1996. Accordingly, it is evident that the Abstract
`
`Books were made available to preregistered meeting participants sometime
`
`between July 12, 1996 (discounted preregistration deadline) and September
`
`15, 1996 (start of the meeting).
`
`Page 4
`
`

`

`Affidavit of JeffKarr
`Page 5
`
`14. The statements on page 4 of the Preliminary Program confirm that the
`
`Abstracts Book was also available to participants during the meeting.
`
`Specifically, participants could pick up the Abstracts Book "on site at the
`
`Preregistration Desk by presenting the Attendee Locator card that is mailed
`
`with the badge." Further, the Abstracts Book was "available at the meeting
`
`for purchase by on-site registrants." Thus, these statements on page 4 of the
`
`Preliminary Program confirm that the latest possible day that the Abstracts
`
`Books containing the Kaken Abstracts were publicly available was the first
`
`day of the 36th ICAAC (i.e. September 15, 1996).
`
`15. Notably, the cover page of the Preliminary Program indicates that the
`
`deadline for receipt of "Late-Breaker" abstracts was August 23, 1996. The
`
`Late-Breaker abstracts were not included in the Abstracts Book. Instead,
`
`they were included in a separate book, the "Program Addendum," that also
`
`contained program listings (the time, date and location where the late
`
`breaking science would be presented). The Program Addendum was made
`
`available to attendees, at the latest, by the time the meeting started on
`
`September 15, 1996.
`
`16. However, the Kaken Abstracts were not among the Late-Breaker abstracts.
`
`Late-Breaker abstracts were assigned identification numbers starting with
`
`Page 5
`
`

`

`Affidavit of Jeff Karr
`Page 6
`
`"LB." In contrast, the Kaken Abstracts were assigned identification
`
`numbers starting with "F" (i.e. "F78," "F79" and "F80"). The "F" notation
`
`at the beginning of each of the Kaken Abstracts means that these abstracts
`
`were included in Section F, entitled "New Antimicrobials (pre US IND)
`
`Including Chenristry and Susceptibility", of the original Abstracts Book.
`
`See Exhibit A, page iii.
`
`17.
`
`I declare that all statements made herein are true. Further, these statements
`
`were made with the knowledge that willful false statements and the like so
`
`made are punishable by fine or in1prisonment, or both.
`
`Signature
`
`Name
`
`Date
`
`I
`l
`
`Jeff Karr
`
`Page 6
`
`

`

`
`EXHIBIT A
`
`
`
`EXHIBIT A
`
`Page 7
`
`

`

`ABSTRACTS
`of the 36th
`I nterscience Conference
`on Antimicrobial Agents
`and Chemotherapy
`
`an Annual Meeting
`of the American Society for Microbiology
`
`September 15-18, 1996
`
`Ernest N. Morial Convention Center
`New Orleans, louisiana
`
`Amercan Society for Microbiology
`Washington, D.C.
`
`Page 8
`
`

`

`© 1996 American Society for Microbiology
`1325 Massachusetts Avenue, N .W.
`Washington, DC 20005-4171
`
`All Rights Reserved
`Printed in the United States of America
`ISBN 1-55581-113-2
`
`Page 9
`
`

`

`CONTENTS
`
`Abstracts in Order of Subject Category:
`
`Subject Category A ........................................................................................................................................................................ 1
`Pharmacokinetics and Pharmacodynamics in Animals or Humans
`
`Subject Category B ...................................................................................................................................................................... 21
`Animal Models, Pathogenesis of Infectious Diseases, Molecular Basis for Pathogenicity
`
`Subject Category C ...................................................................................................................................................................... 34
`Antimicrobial Resistance and Action: Genetics, Mechanisms, Epidemiology
`
`Subject Category D ...................................................................................................................................................................... 60
`Laboratory Tests (Excluding Viral) for Diagnosing Infections; Methods for Susceptibility Testing
`
`Subject Category E ...................................................................................................................................................................... 81
`In Vitro Antimicrobial Susceptibility Studies; Smveillance and Detection of Antimicrobial Resistance; Drug
`Interactions and Combinations
`
`Subject Category F ..................................................................................................................................................................... 100
`New Antimicrobials (pre US IND) Including Chemistry and Susceptibility
`
`Subject Category G .................................................................................................................................................................... 143
`Immunology and Host Defenses; Bacterial Vaccines, Immunomodulators, and Immune Response
`
`Subject Category H .................................................................................................................................................................... 163
`Virology: Diagnostics, Pathogenesis, Natural History, Antiviral Drugs, and Vaccines
`
`Subject Category I ...................................................................................................................................................................... 186
`HIV and Other Retroviruses
`
`Subject Category J ..................................................................................................................................................................... 218
`Nosocomial Infections and Surgical Infections and Related Epidemiologic Studies
`
`Subject Category K .................................................................................................................................................................... 249
`Community-Acquired Infections, Including OB GYN and STD Infections, and Related Epidemiologic Studies
`
`Subject Category L, M .............................................................................................................................................................. 280
`Clinical Trials of Antimicrobial Agents & Unique and Instructive Clinical Observations
`
`Subject Category N .................................................................................................................................................................... 293
`Pharmacoeconomics and Managed Care
`
`Subject Index ............................................................................................................................................................................. 327
`
`Participant Index ........................................................................................................................................................................ 337
`
`iii
`
`Page 10
`
`

`

`Monday, Session 50
`
`ABSTRACTS OF THE 36th ICAAC
`
`F78 KP-103, 1 Novel Topical Antifungal Trilzole:
`Structure-Activity Relationships ol Azolylamlne Derlvatlns.
`H.OGURA•, H.KOBAYASID,
`K.NAGAI,
`T.NISHIDA,
`T.NAITO,
`Kalcen Pharm Co., LTD.,
`Y.TATSUMI, M .YOKOO sod T.ARIKA.
`Kyoto, Japan.
`a
`agent, we have prepared
`antifungal
`for
`In a search
`an
`variety of new azolylamine derivatives with general
`formula (I) and
`measured
`in vitro activity. MIC values (IJ.g/ml) were shown below.
`crz Media'
`O.D25 A
`0.2
`B
`0.78
`B
`B
`0.39
`
`2
`KP-103
`Fungi
`I
`<0.025 <0.025 <0.025
`C. albicans KC-03
`Cr. neoformans KC-201 0.05
`0.2
`0.1
`A. fumigatus KA-01
`. 0.2
`0.2
`1.56
`T. nl#:ntagrophytes KD-04 0.39
`0.78
`1.56
`B; sabouraud dextrose agar.
`'A; SAAMF broth.
`at
`We
`found
`that
`~-yclic amine having methylene group
`lhe
`for a broad antifungal
`lhe 3 position
`is necessary
`specuum
`and
`a poleD! activity. KP-103 which has a
`(2R,3R)-absolute configuration
`4-metllylenepiperidine moiety,
`showed
`potent
`the most
`a
`and
`lll:tivity
`and signilicanUy
`lower MIC values
`than ciOirimazole(CTZ).
`
`4
`0.05 0.2
`0.78 6.25
`1.56 50.0
`3.13 2.5.0
`
`r:l'-103
`
`rao. ic r•~ i c r~ l c r~i c
`
`~- 2R,3R
`Q Q-N~ 0
`
`F75
`
`SSY726, a New Triazole Antifungal Agent: in vitro and in vivo
`Evaluation. K. YOKOY AMA• , L. WANG, and M. MIY AJI.
`Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba
`University, Chiba, and A. IWASA. Research Laboratories, SS
`Pharmaceutical Co., Ltd., Narita, and Y. Ikeda. Research Laboratories,
`Y oshitomi Pharmaceutical Industries, Ltd., Fukuoka, Japan.
`The in vitro and in vivo antifungal activity of SSY726, a new antifungal
`agent, was compared with that of fluconazole (FLCZ) against Candida spp.,
`Cryptococcus neoformans, and Aspergillus spp .. Minimum inhibitory
`concentration (MIC) was determined to estimate the in vitro activity by the
`twofold agar dilution method. The MIC ranges were as follows: SSY726,
`0.5 - 4 JJ ghnl; FLCZ, 0.5 - 8 with synthetic amino acid medium for fungal
`(SAAMF), SSY726, 128 - >512; FLCZ, .512 - >512 with RPMI-1640
`MOPS medium (RPMI) against C.albicans (30 strains). SSY726, 4 - 256
`I' g/ml; FLCZ, 4 - 2.56 with RPM! against C.neoformans (30 strains).
`SSY726, 32 - >.512 JJ g/ml; FLCZ, 128 - >512 with SAAMF against
`A..fwnigatus (30 strains).
`.
`The in vivo activity was measured following one time on day 0 (in
`Candida and Cryptococcus models) or once a day on five successive days
`(in Aspergillus models) injection of the agent into .5-week old, ICR male
`mice. The efficacy was determined by the dose of agent necessary to
`achieve a certain TIC (treated group/control group) ratio of survival days. In
`the candidosis model, 0.313 mglkg of SSY726 or 5 mg/kg of FLCZ was
`required to achieve 300% of TIC ratio, respectively. In the cryptococcosis
`model, S mglkg of SSY726 or 20 mg/kg of FLCZ achieved 122 % of TIC.
`In the aspergillosis model, no significant difference in efficacy was detected
`between these two agents. Our study suggests that the in vivo efficacy of
`SSY726 is higher than that of FLCZ against Candida and Cr,ptococcus.
`
`F76
`
`Efficacy of SSY126 on Systemic Candidosis and Cryptococcosis
`in Neutropenic Mice. M. MATSUMOTO*, T . ASAOKA, and A.
`1W ASA. Research Laboratories, SS Pharmaceutical Co., Ltd., Narila, and
`Y. IKADA, K. YAMAMOTO, and F. HIRAYAMA. Research
`Laboratories, Yoshitomi Pharmaceticallndustries, Ltd., Fukuoka, Japan.
`SSY726:(R)-(-)-3-methyl-3-methylsulfonyl-1-(1 H-1, 2, 4- triazol - 1-yl)
`2-[4-(trifluoromethyl)phenyl]butan-2-ol is a new triazole antifungal agent.
`Its in vivo efficacies on the basis of prolongation of survival were tested in
`comparison with those of fluconazole (FLCZ). SSY726 showed more
`potent activity than FLCZ with a single i.v. treatment on systemic
`candidosis (C.albicans IFM 40009) and cryptococcosis (C.neoformans
`TIMM 1855) in mice. In normal mice, minimum effective doses were
`0.313 mglkg of SSY726 and 1.25 mg/kg of FLCZ on candidosis, and 20
`mg/kg of SSY726 and over 20 mglkg of FLCZ on cryptococcosis. In
`neutropenic mice (cyclophosphamide 100 mg/kg i.p. treated: Cy), they
`were 0.313 mg/kg of SSY726 and 5 mg/kg of FLCZ on candidosis, and
`1.25 mg/kg of SSY726 and 20 mg/kg of FLCZ on cryptococcosis. In
`5-fluorouracil treated mice (150 mg/kg i.p.), they were 0.313 mg/kg of
`SSY726 and 5 mglkg of FLCZ on candidosis. SSY726 efficacy was also
`compared to that of FLCZ after repeated treatments. In normal mice, i.v.
`treatment of SSY726 every two days or daily doses of 1.25 mg/kg for
`eight days showed an equivalent effect to that of i.v. daily treatment of 5
`mg/kg FLCZ for eight days. In neutropenic mice (Cy}, i.v. treatment of
`SSY726 every four days doses of 1.25 mglkg for eight days showed an
`equivalent effect to that of i.v. daily treatment of 5 mg/kg FLCZ for eight
`days. Thus, SSY726 was more effective than FLCZ in the systemic
`infection with C.albicans and C.neofortMns, especially in neutropenic
`mice.
`
`F77
`
`Anticryptococcal Activity of SSY726, a New Triazole Antifungal
`Agent, in a Murine Pulmonary Infection Model. Y. IKEDA • , K.
`YAMAMOTO, and F. HIRAYAMA. Research Laboratories, Yoshitomi
`Pharmaceutical Industries, LTD., Fukuoka. M. MATSUMOTO, T .
`ASAOKA, and A. IWASA, Central Research Laboratories, SS
`Pharmaceutical Co., LTD., Chiba, Japan.
`SSY726, a new iriazole antifungal agent, was evaluated for
`anticryptococcal activity in normal or neutropenic mice. The leukopenic
`mice with cyclophosphamide (CY, 100 mg/kg, i.p.), 5-fluorouracil (5-FU,
`150 mg/kg, i.p.) or prednisolone (PDN, 50 mg/kg s.c.), and normal mice
`were inoculated intranasally with 1.7 - 3.0 x 10~ cells of Cryptococcus
`neoformans TIMM 1855. Intravenous treatment with SSY726 or
`fluconazole (FLCZ) was initiated I hour after the challenge, and was
`followed by once daily, every two days or every four days for 8 days.
`Therapeutic effect was estimated by the reduction of viable cell counts
`(CFU) in lungs at day 10 after the infection. In once daily for eight
`successive days injection, SSY726 significantly reduced CFU in lungs at
`a dose of 0.31 mg/kg/day in CY- and 5-FU-treated mice, and itt a dose of
`5 mg/kg/day in normal and PDN-treated mice. FLCZ reduced CFU in
`lungs at a dose of 5 mg/kg/day and 20 mglkg/day in CY- and
`5-FU-treated mice, respectively, but did not up to SO mg/kglday in normal
`and PDN-treated mice. Every four days treatment with 5 mglkglday of
`SSY726 (total dose: 10 mg/kg) showed the effect compara6Ic to once
`daily for eight successive days treatment with 20 mglkg/day of FLCZ
`(total dose: 160 mglkg) in CY-treated mice. These results suggest that
`SSY726 is more effective than FLCZ in the therapy of pulmonary
`cryptococcosis in compromised humans.
`
`H
`
`I"'
`"'
`
`I
`F
`Am • aJbltilured aaPo poup
`
`F
`
`Ala
`
`\
`
`\
`
`\
`
`....
`-H
`~ llo
`
`In VItro Activity of KP-103, a Novel Topical Antifungal TrtiiZDie.
`F79
`Y. TATSUMI', M. YOKOO, T. ARIKA, H. OGURA, K. NAGAI, and T. NAITO.
`Kaken Pharmaceutical Co. Ud., Kyoto, Japan, H. YAMAGUCHI, Telkyo Unlv.,
`Tokyo, Japan.
`The in vitro activity of KP-1 03, a 1riazole having 4-methyleneplperidlne
`moiety at the C-3 position, was compared with that of dotr1mazole (CTZ),
`lanoconazole (LCZ), and buteoaftne (BTF) against
`neticonazole
`(NCZ),
`pathogenic fungi. MIC.O values ~g/ml) were shown below.
`KP-103 crz NCZ
`BTF Media"
`Fungi (No. of strains)
`LCZ
`C. alb/cans (44)
`A
`>8.0
`0.0313 0.0625 0.25
`0.002
`c
`M. furfur (6)
`12.5
`0.025
`6.25
`3.13
`0.78
`Asperg/Uus spp.(15)
`0.25
`0.0625 2.0
`0.25
`0.002
`A
`B
`T. rubrum (39)
`0.0078
`0.125
`0.5
`0.25
`0.0076
`T. mentsgrophytBs (26) 0.25
`B
`0.25
`0.0156
`0.25
`0.0313
`' A. 0.2M MOPS-bUftored RPMI 1&10, pH 7.0; 8, Soboulaud -
`bn:lUI;
`C. rnecll.m C (Foorgomann J ol 1L Nil Dorm. V-.ol. Suppl 88: 1-23, 1878).
`KP-1 03 was the most active against C. albicsns and M. futfur among the
`tested Q-uos. Its activity against TrichophytOn spp. was almost equal to thai
`of CTZ and NCZ, but was weaker than thai of LCZ and BTF.
`Anti-T. mentsgrophytss activities of the ref8lence drugs -
`reduced by
`1he addition of human serum and horny materials as repor1ed, whAe that of
`KP-1 03 was not affected. Fw1ha!more, Anti-T. mentsgropytes activity of KP-
`103 on the stripped human horny layer was equal to thai of LCZ and BTF.
`n-e results reflected in vivo elficacies.
`In summary, KP-103 has a broad antifungal spectrum and could keep
`a high activity In the homy layer where fungi reside.
`
`Therapeutic Emcacy of KP-103, a Novel Topical Antifungal
`FBO
`Trtazola, on Experimental Superficial Mycoala. Y. TATSUMI", M. YOKOO,
`T. ARIKA, H. OGURA, K. NAGAI, and T. NAITO. Kaken Pharmaceutical Co.
`Ud., Kyoto, Japan, H. YAMAGUCHI, Teikyo Unlv., Tokyo, Japan.
`The therapeu1ic efficacy of KP-103 on dermalomycosls models In guinea
`pig was compared with that of neticonazloe (NCZ), lanoconazole (LCZ),
`butenafine (BTF), and clotrimazole (CTZ). One % solution of each drug was
`topically applied once a day. Two days after last application, skin blocks or
`cuhured. Rate of complete cure was expressed by 1he
`homogenates -
`percentage of mycologically cured animals In Infected animals (n• 10).
`
`The elticacy of KP-103 on dermalophytosis models was superior to that
`of NCZ and almost equal to that of LCZ and BTF. KP-1 03 was ellectlve on
`skin candkiasis, while the other Q-uos were not. To clarify the duration of
`retention time of 1he drug in skin after topical application, the prophytactlc
`effect of KP-103 on dermatophytosis model was examined. KP-103 exerted
`prophylactic effect with 90% cure rate at applcatlon of 46h before Infection.
`In summary, the excellent atflcacy of KP-103 on dermalophytosls and
`skin canddlasis may be attributed to Its high activity and long time retention
`In the horny layer.
`
`113
`
`Page 11
`
`

`

`
`EXHIBIT B
`
`
`
`EXHIBIT B
`
`Page 12
`
`

`

`•
`
`American
`Society for
`Microbiology
`
`•
`
`New Orleans, Louisiana
`September 15-18, 1996
`
`lnterscience Conference on
`Antimicrobial Agents and
`Chemotherapy
`
`D EADLINE D ATES
`Late-Breaker Absrract Receipt .. August 23, 1996
`Discounted Preregistration
`and Housing Deadline .. . ........ July 12, 1996
`Advance Registration
`and Housing Deadline . . . . .... . August 9, 1996
`
`Ernest N. Morial Convention Center
`New Orleans, Louisiana
`
`Supplement to ASM News
`
`Page 13
`
`

`

`Program and Abstracts
`
`All registrants will receive a
`copy of the Program and the
`Abstracts Books as pan of the
`registration fee. These books are
`mailed to all U.S. and
`Canadian preregistrants.
`Canadian preregistrants can pay
`an optional fee of $20 to have
`these books shipped via Federal
`Express (see registration form).
`Preregistered attendees in inter(cid:173)
`national locations may receive
`the Program and Abstracts
`Books (via Federal Express)
`before the meeting for an addi(cid:173)
`tional fee of $30 {see registra(cid:173)
`tion form). If the optional
`delivery fee is not paid by an
`international preregistrant, then
`one copy of each book can be
`picked up on site at the
`Preregistration Desk by present(cid:173)
`ing the Attendee Locator card
`that is mailed with the badge.
`Every effort is made to ensure that Abstracts Books are
`available at the meeting for purchase by on-site registrants.
`However, should on-site registration exceed expectations,
`we cannot guarantee that our supply of Abstracts Books
`will meet the needs of all on-site registrants. If available,
`copies of the Abstracts Book may be ordered after the meet(cid:173)
`ing by calling ASM Publication Sales at 703-787-3305.
`
`Page 14
`
`